Wolters Kluwer Health has announced the appointments of Gregory Samios as President & CEO of Clinical Effectiveness and Dr. Peter Bonis as Chief Medical Officer (CMO) of the division, effective December 1, 2021. The appointments reflect Wolters Kluwer’s continued focus on advancing healthcare technology and growing expert solutions across the continuum of healthcare.
As President and CEO for Clinical Effectiveness, the largest business within Wolters Kluwer’s Clinical Solutions group, Samios succeeds Dr. Denise Basow, who is leaving Wolters Kluwer after 25 years of service. Samios brings decades of experience as a customer-focused executive in the healthcare and legal information sectors. Most recently, he served as President and CEO of Health Learning, Research & Practice (HLRP). Throughout his career, Samios has been passionate about working together with customers to understand their unique challenges and deliver deep impact where it matters most. He employs lean principles to all aspects of business transformation to stimulate innovation and cultivate industry partnerships as vital to building value creation. Samios joined Wolters Kluwer in 2014, serving as President and CEO of the Wolters Kluwer Legal & Regulatory U.S. business before moving to the Health Division to lead HLRP in 2019.
Dr. Bonis, who has served as Chief Medical Officer of Clinical Effectiveness since 2015, will now expand his scope to oversee division-wide industry partnerships, research and development initiatives, and deep collaborations with customers and partners. He joined Wolters Kluwer in 2008 as part of the acquisition of UpToDate where he has served since 1998. He was instrumental to the development of UpToDate into the leading clinical decision support tool used by doctors globally and in bringing the drug information and patient engagement products together with UpToDate under Clinical Effectiveness.
The Clinical Effectiveness business, which is part of Clinical Solutions, includes UpToDate clinical decision support solutions, Lexicomp® and Medi-Span® clinical drug information, and the Emmi® patient engagement solutions.
Click here to read the original press release.
